HGC Investment Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

HGC Investment Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,383	Closed	-$2K	–	236
2023 Q1	$2K	Hold	26,383	–	–	﹤0.01%	213
2022 Q4	$1K	Buy	+26,383	New	+$939	﹤0.01%	314

HGC Investment Management's EUCRW Position: Q2 2023 in Review

HGC Investment Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 26,383 shares — an estimated $2K sold.

HGC Investment Management first reported a position in EUCRW in Q4 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

HGC Investment Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
HGC Investment Management sold 26,383 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $2K.
HGC Investment Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q4 2022 and held it in 2 quarters.
HGC Investment Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $2K in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on HGC Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.